- California: Applications are being accepted for the third class of the Cedars-Sinai Accelerator powered by Techstars, which connects health care companies with stakeholders and decision-makers at Cedars-Sinai with the goal of making commercial deals. After completing the program, the companies in the first class raised more than $11 million in venture capital financing, and according to the Techstars blog, the second class—currently in program—is "is showing equally strong potential." The deadline to apply for the upcoming class is June 9, and the next round of the program will start Sept. 12 (Kozlov, Techstars Blog, 3/13).
- Missouri: Kristen DeHart on June 2 began her role as CEO of Excelsior Springs Hospital, following the retirement of former CEO Sally Nance. DeHart, who has an MBA from Western Governors University, previously served as division VP of rehabilitation services for Hospital Corporation of America and, most recently, as CEO of Rehabilitation Hospital of Overland Park (Vaidya, Becker's Hospital Review, 6/1).
- Texas: State lawmakers have sent a bill (HB 810) to Gov. Greg Abbott (R) that would authorize "investigational stem cell treatments," or those stem cell therapies that are currently in trial or have not generally garnered FDA approval, Vocative reports. If approved, the measure would make Texas the first state to explicitly recognize such treatments, which many clinics current offer without any official legal validation. Under the bill, providers would have to deliver the treatments at a hospital or ambulatory medical center, with the approval of an institutional review board. If approved, the measure would take effect on Sept. 1 (Joseph, STAT News, 5/30; Ossola, Vocativ, 5/30).
Access the finance leader's resource guide
Leaders in Congress and the Trump Administration are reassessing their approach to repealing and replacing the Affordable Care Act. No matter the outcome, one thing is for sure: there will be serious and long-lasting financial consequences for hospitals.
This guide is intended to help you and your finance teams operate in this uncertain time. Inside, you'll find the information and no-regrets strategies needed to support mission and margin in any regulatory environment.